Filtered By:
Source: American Heart Journal
Condition: Heart Attack
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 253 results found since Jan 2013.
Risk of obstructive coronary artery disease and major adverse cardiac events in patients with non-coronary atherosclerosis: Insights from the veterans affairs clinical assessment, reporting, and tracking (CART) program
ConclusionsIn patients undergoing coronary angiography, non-coronary atherosclerosis was associated with increased burden of oCAD and adverse events post PCI.
Source: American Heart Journal - April 16, 2019 Category: Cardiology Source Type: research
Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design
ConclusionThis is the largest randomized trial to test if influenza vaccine compared to control reduces adverse vascular events in high risk individuals.Trial registration number:Clinicaltrials.govNCT02762851
Source: American Heart Journal - March 12, 2019 Category: Cardiology Source Type: research
Neck circumference and cardiovascular outcomes: Insights from the Jackson heart study
ConclusionsIn this large cohort of African American individuals, a larger NC was associated with increased risk for HF hospitalization following adjustment for age and sex, but this risk was not statistically significant after adjusting for other clinical variables. Although NC is not independently associated with increased risk for cardiovascular events, it may offer prognostic information particularly related to HF hospitalization.
Source: American Heart Journal - March 9, 2019 Category: Cardiology Source Type: research
Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design
ConclusionsThe TICO trial is an ongoing trial evaluating the efficacy and safety of ticagrelor monotherapy following 3-month DAPT exclusively in ACS patients treated with uniform BP-SES. It may provide novel insights regarding the need for adjusted use of DAPT for rebalancing risk–benefit in current practice and changing from the conventional concept of aspirin maintenance to a ticagrelor-based regimen in the management of ACS.
Source: American Heart Journal - March 9, 2019 Category: Cardiology Source Type: research
Outcomes after STEMI in old multimorbid patients with complex health needs and the effect of invasive management
ConclusionsMultimorbid older people with complex health needs and STEMI had high rates of new ischemic events and death. In this cohort of older, high risk STEMI patients, an invasive strategy was associated with lower event rates. Randomized studies are needed to clarify whether these high risk patients who might benefit from invasive care are being managed too conservatively.
Source: American Heart Journal - February 1, 2019 Category: Cardiology Source Type: research
Association of Frailty and Cognitive Impairment with benefits of Oral anticoagulation in patients with atrial fibrillation
ConclusionThose with cognitive impairment or frailty in AF had higher predicted risk for stroke and higher observed mortality, yet were less likely to be treated with OAC. Despite this, the benefits of OAC were similar in patients with and without cognitive impairment or frailty.
Source: American Heart Journal - January 30, 2019 Category: Cardiology Source Type: research
Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons
ConclusionsAmong PWH with statin indication(s), blacks and Hispanics were less likely than whites to have been prescribed a statin. These racial/ethnic disparities were less pronounced among uninfected persons. There were significant differences in type of statin used for PWH compared to uninfected matched controls. Future efforts addressing disparities in CVD prevention among PWH are warranted.
Source: American Heart Journal - January 25, 2019 Category: Cardiology Source Type: research
Radial versus femoral vascular access in ST-elevation myocardial infarction: Are the results of femoral operators unfairly represented in observational research?
ConclusionDefault femoral operators achieved comparable outcomes when compared to default radial operators. The less favorable outcomes observed in FA cases may result from its selective use by radial operators in high risk cases.
Source: American Heart Journal - January 16, 2019 Category: Cardiology Source Type: research
C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left Main coronary artery disease: Analysis from the EXCEL trial
Conclusions: In patients with LMCAD undergoing revascularization, elevated baseline CRP levels were strongly associated with subsequent death, MI and stroke at 3 years, irrespective of the mode of revascularization. Further studies are warranted to determine whether anti-inflammatory therapies may improve the prognosis of high-risk patients with LMCAD following revascularization.
Source: American Heart Journal - January 12, 2019 Category: Cardiology Source Type: research
Differences in Statin Utilization and Lipid-Lowering by Race, Ethnicity, and HIV Status in a Real-World Cohort of Persons with Human Immunodeficiency Virus and Uninfected Persons
ConclusionsAmong PWH with statin indication(s), Blacks and Hispanics were less likely than whites to have been prescribed a statin. These racial/ethnic disparities were less pronounced among uninfected persons. There were significant differences in type of statin utilized for PWH compared to uninfected matched controls. Future efforts addressing disparities in CVD prevention among PWH are warranted.
Source: American Heart Journal - December 21, 2018 Category: Cardiology Source Type: research
Generalizability of the FOURIER Trial to Routine Clinical Care: Do Trial Participants Represent Patients in Everyday Practice?
ConclusionsOne in seven ASCVD patients in practice would have qualified for FOURIER. The excluded and under-represented populations were at a particularly low or high cardiovascular risk. Statin therapy was under-used and physicians may need to evaluate adherence before adding PCSK9i.
Source: American Heart Journal - December 19, 2018 Category: Cardiology Source Type: research
Yao generalizability of FOURIER to routine practice
ConclusionsOne in seven ASCVD patients in practice would have qualified for FOURIER. The excluded and under-represented populations were at a particularly low or high cardiovascular risk. Statin therapy was under-used and physicians may need to evaluate adherence before adding PCSK9i.
Source: American Heart Journal - December 16, 2018 Category: Cardiology Source Type: research
Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation: Design and rationale of the TOMAHAWK trial
ConclusionThe TOMAHAWK trial will address the unresolved issue of timing and general indication of angiography after OHCA without ST-segment elevation.
Source: American Heart Journal - December 12, 2018 Category: Cardiology Source Type: research
Rationale and Design of the Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study
Publication date: Available online 29 September 2018Source: American Heart JournalAuthor(s): Aruna D. Pradhan, Nina P. Paynter, Brendan M. Everett, Robert J. Glynn, Pierre Amarenco, Marshall Elam, Henry Ginsberg, William R. Hiatt, Shun Ishibashi, Wolfgang Koenig, Børge G. Nordestgaard, Jean-Charles Fruchart, Peter Libby, Paul M RidkerAbstractObservational, genetic, and experimental data indicate that triglyceride rich lipoproteins (TRLs) likely participate causally in atherothrombosis. Yet, robust clinical trial evidence that triglyceride (TG) lowering therapy reduces cardiovascular events remains elusive. The selective p...
Source: American Heart Journal - October 4, 2018 Category: Cardiology Source Type: research
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)
ConclusionThe results from the VERTIS-CV trial will define the CV and renal safety and efficacy of ertugliflozin in patients with T2DM and ASCVD.ClinicalTrials.gov identifier: NCT01986881
Source: American Heart Journal - September 6, 2018 Category: Cardiology Source Type: research
